Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) dropped 6.4% during mid-day trading on Wednesday . The company traded as low as GBX 0.95 ($0.01) and last traded at GBX 0.96 ($0.01). Approximately 6,211,438 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 10,021,008 shares. The stock had previously closed at GBX 1.03 ($0.01).
Hemogenyx Pharmaceuticals Stock Up 9.8 %
The company has a 50 day moving average of GBX 1.34 and a 200-day moving average of GBX 1.36. The company has a debt-to-equity ratio of 92.09, a current ratio of 4.38 and a quick ratio of 6.72. The company has a market cap of £15.75 million, a P/E ratio of -114.00 and a beta of 3.14.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Read More
- Five stocks we like better than Hemogenyx Pharmaceuticals
- 10 Best Airline Stocks to Buy
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Health Care Stocks Explained: Why You Might Want to Invest
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- How to Use Stock Screeners to Find Stocks
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.